Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has announced the final terms for its rights issue and potential overallotment issue, aimed at raising funds for an expanded Phase II study. The rights issue is expected to raise approximately 86 million SEK initially, with additional funds possible through warrants, supporting the company’s efforts to enhance its clinical data and strengthen its position in the oncology sector.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, focusing on developing treatments to improve the outlook for cancer patients worldwide. The company is listed on Nasdaq Stockholm and is involved in clinical studies to generate new data for its medical advancements.
Average Trading Volume: 562,276
Current Market Cap: SEK187.8M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue